An interventional study of Nutritional Support Team and Docetaxel in Esophageal Neoplasms and Adverse Drug Event, sponsored by The First Affiliated Hospital with Nanjing Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-05.
Sponsored by The First Affiliated Hospital with Nanjing Medical University · Not applicable, Interventional, and Supportive care
This study is a randomized, open, parallel controlled clinical trial. The main purpose of this study was to compare the changes in body weight/body mass index (BMI) before and after treatment between the two groups of patients with NST full-course nutritional management and without NST full-course nutritional management.
The secondary objective was to compare the quality of life, nutritional status, immune function and inflammatory response, adverse reactions of radiotherapy and chemotherapy, and short-term/long-term efficacy between the two groups.
The treatment plan was: esophageal cancer with routine nutrition guidance as the control group, and the NST whole-process intervention guidance as the experimental group.
1. Experimental group: NST whole-course intervention
(1) Nutritional therapy: The nutritional program was the same as that of the experimental group, and the patients performed it themselves.
(2) Concurrent chemoradiotherapy: the same as the experimental group.
Efficacy evaluation:
(4) Intestinal mucosal barrier and intestinal flora (5) Adverse reactions of radiotherapy and chemotherapy (6) Short-term/long-term efficacy (5) Evaluation of treatment side effects (6) Short-term/long-term efficacy
This study is a randomized, open, parallel controlled clinical trial. The main purpose of this study was to compare the changes in body weight/body mass index (BMI) before and after treatment between the two groups of patients with NST full-course nutritional management and without NST full-course nutritional management.
The secondary objective was to compare the quality of life, nutritional status, immune function and inflammatory response, adverse reactions of radiotherapy and chemotherapy, and short-term/long-term efficacy between the two groups.
The treatment plan was: esophageal cancer with routine nutrition guidance as the control group, and the NST whole-process intervention guidance as the experimental group.
1. Experimental group: NST whole-course intervention
Nutritionists formulate nutritional programs and manage them in a refined manner. On the basis of the patient's natural diet (food and homogenate meal), enteral nutritional preparations or parenteral nutritional supplements are given according to the patient's gastrointestinal obstruction, dietary structure, and food intake. Energy 30-35kcal/kg/d, protein 1.2-1.5g/kg/d. Enteral nutrition administration route: oral or tube feeding or ostomy, oral feeding is preferred; severe obstruction of eating or oral can not meet the target nutrition, choose tube feeding or ostomy. When it is expected that enteral nutrition cannot meet 60% of the target energy requirement for 3 to 5 days, choose parenteral nutrition. The enteral nutritional preparation adopts the whole protein enteral nutritional preparation Nengquan, and/or the tumor nutritional preparation Ruineng, and/or whey protein powder.
Enteral nutrition preparations should choose Nengquan, and the dose of Nengjian: (a) No/mild obstruction, can eat ordinary diet, the food intake is not reduced or less than 1/3 before the disease, and 10-15kcal of Nengjian is given. /kg/d; (b) moderate obstruction, can eat soft food, the food intake is less than 1/3\~2/3 before the disease, and can give 15-20kcal/kg/d; (c) severe obstruction, can not Eating, the food intake is reduced by >= 2/3 compared with that before the disease, and can be given 20-25kcal/kg/d of all-vegetarian food; Dosage of whey protein powder: (a) albumin 35\~40g/L, supplemented with whey protein powder 10g; (b) albumin 30\~35g/L, supplemented with whey protein powder 20g; (c) albumin \<30g /L, supplement whey protein powder 30g.
Nutritionists urge patients to report daily to ensure adequate energy and protein supplementation.
2. Control group: routine nutrition guidance for esophageal cancer
Efficacy evaluation:
(4) Intestinal mucosal barrier and intestinal flora (5) Adverse reactions of radiotherapy and chemotherapy (6) Short-term/long-term efficacy (5) Evaluation of treatment side effects (6) Short-term/long-term efficacy Statistical methods: All statistical tests were two-sided, and P values \< 0.05 were considered statistically significant. Data are presented as x ±s. Quantitative data were analyzed by t test and variance analysis, qualitative data were analyzed by X2 test, and survival data were analyzed by Kaplan Meire method, logrank test, and Cox regression.
1,631 studies on the registry are indexed under Esophageal Neoplasms; 469 are open to participants now.
This study's planned enrollment of 210 is above the median of 60 across 1,198 interventional studies indexed under Esophageal Neoplasms.
Browse Esophageal Neoplasms studies →The First Affiliated Hospital with Nanjing Medical University is the lead sponsor of 563 studies on the registry; 311 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The function of major organs (bone marrow, liver, kidney function) 7 days before treatment, meet the following criteria: Blood routine examination standards (without blood transfusion within 14 days):
Hemoglobin (HB) ≥ 100g/L;
White blood cells (WBC) ≥ 4×109/L; Absolute neutrophil count (ANC) ≥1.5×109/L;
The biochemical examination shall meet the following standards:
Total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal (ULN);
Alanine aminotransferase (ALT) and aspartate aminotransferase AST ≤ 1.5 times ULN;
Exclusion Criteria:
1. Nutritionists formulate nutritional programs and manage them in a refined manner. The nutritionist urges the patient to report daily to ensure that the patient's energy and protein are in place 2. Radiotherapy 3. chemotherapy
Dietary Supplement: Nutritional Support Team · Drug: Docetaxel · Drug: cisplatin · Radiation: Radiotherapy
1. Patients perform their own nutrition regimen, and the nutritionist is not involved in management 2. Radiotherapy 3. chemotherapy
Drug: Docetaxel · Drug: cisplatin · Radiation: Radiotherapy
Nutritionists formulate nutritional programs and manage them in a refined manner. On the basis of the patient's natural diet (food and homogenate meal), enteral nutritional preparations or parenteral nutritional supplements are given according to the patient's gastrointestinal obstruction, dietary structure, and food intake. Energy 30-35kcal/kg/d, protein 1.2-1.5g/kg/d. Enteral nutrition administration route: oral or tube feeding or ostomy, oral feeding is preferred; severe obstruction of eating or oral intake cannot meet the target nutrition, choose tube feeding or ostomy. When it is expected that enteral nutrition cannot meet 60% of the target energy requirement for 3 to 5 days, choose parenteral nutrition. The enteral nutritional preparation adopts the whole protein enteral nutritional preparation Nengquan, and/or the tumor nutritional preparation Ruineng, and/or whey protein powder.
Also known as: taixinsheng
60-75 mg/m2, d1, at least 2 cycles in parallel with radiotherapy
Also known as: chemotherapy
cisplatin 25mg/m2 d1-3, 21-28d/cycle. at least 2 cycles in parallel with radiotherapy
Also known as: chemotherapy
image-guided intensity-modulated radiotherapy (IGRT) or intensity-modulated radiotherapy (IMRT); Irradiation targets include primary lesions, clinical targets, positive lymph nodes, and lymph node drainage areas. Dose splitting/prescription dose, 95% volume PGTV-T60-66Gy/30-35 times, PGTV-N 60-66Gy/30-35 times, PCTV-T 46-50Gy/23-25 times, PCTV-N46-50Gy/23-25 times.
Body weight and body mass index (BMI)
BMI = weight ÷ height2. (Unit of weight: kg; Height unit: meters),During treatment: Body weight was recorded daily and BMI was recorded weekly,BMI values are recorded every Friday
Time frame: up to 3 years
Quality of life score
EORTCQLQ-C30,EORTC:The European O-rganization for Reasearch and Treatment of Cancer),QOL-C30 (Quality of Life Questionnare-Core 30,Assessments are conducted every two weeks on Fridays of the second week
Time frame: up to 3 years
hemoglobin
Compare the numerical changes of hemoglobin every two weeks
Time frame: up to 3 years
serum albumin
Compare the numerical changes of serum albumin every two weeks
Time frame: up to 3 years
ORR
Proportion of patients with reduction in tumor burden of a predefined amount, including complete remission and partial remission
Time frame: through study completion, an average of 36 month
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2021 (actual). Primary completion is estimated for Dec 2024, 47 months after the start.
Of 178 non-industry interventional studies with no phase under Esophageal Neoplasms, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 98. This study's planned 47 months is close to that.
Counting every sponsor, half of 183 studies reached it within 51 months; a quarter within 28 and three quarters within 98.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nimotuzumab
The First Affiliated Hospital with Nanjing Medical University →